Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Helwan University
Modality
mixture
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07171827CT.gov Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT05008224CT.gov Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | — | Completed | — | — | — |
NCT03712202CT.gov Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03527628CT.gov OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | — | Unknown | — | — | — |
NCT02661503CT.gov HD21 for Advanced Stages | — | Unknown | — | — | — |
NCT02166463CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bleomycin (this asset) | Helwan University | P3 | B · 62 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Adriamycin | Michael Spinner, MD | P3 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Brentuximab Vedotin | National Cancer Institute (NCI) | P3 | BB |
| Gls-010 | Guangzhou Gloria Biosciences Co., Ltd. | P3 | BB |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for Bleomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P4 | BB · 71 |
| Hodgkins Lymphoma | — | P4 | BB · 71 |
| Extragonadal Germ Cell Tumor | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bleomycin in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bleomycin-classic-hodgkin-lymphoma-53790
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →